Hypoplastische Anämien

Niemeyer, Charlotte M.; Meerpohl, Joerg J

doi:10.1007/3-540-29036-2_6

Cited by 1 publication

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It became clear that the number of different substances is too large for joint statistical analysis and some substances are applied rarely and therefore allow no statistical analysis. Other groups working on late effects of chemotherapy had been using the solution of grouping substances by pharmacologic principles, 1,2 usually using a conversion factor before aggregating cumulative doses in a substance group (e.g., References 3–8). Clinical replacement rules require conversion factors, too 9,10 .…”

Section: Introductionmentioning

confidence: 99%

Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors

Ressing

Becker

Müller³

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

Background Epidemiological research on late effects of therapy shows the necessity to aggregate chemotherapy agents to substance classes. This requires using conversion factors by substance classes. Aims The aim of this study was to identify previously used conversion factors from the literature, to present a novel approach for additional factors, and to compare these approaches. Methods and Results A literature review was performed, which identified two main principles of deriving conversion factors: effect‐equivalence and equimolar. Thirty‐five articles presenting effect equivalence‐based factors in the widest sense were found in the literature. Ten articles presented the equimolar approach which can be applied to almost all chemotherapy substances. Based on a comprehensive list of treatment protocols used in German pediatric oncology, we derived alternative conversion factors from typical doses. We compared the conversion factors using Pearson correlation coefficients and linear regression. At least two types of conversion factor were available for each of the 49 substances included. The equivalent effect‐based and the typical dose‐based factors were highly correlated with a regression coefficient close to 1. The equimolar factors are independent. Conclusions For substances for which no conversion factor based on some type of effect equivalence has been published so far, a factor based on a typical doses‐approach may be used in epidemiological late effects research. Doses aggregated based on the equimolar approach may not be compatible with doses aggregated based on equivalent effects.

show abstract

Section: Introductionmentioning

confidence: 99%